Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer
Background. When associated with isolated four or fewer liver foci, metastatic colorectal cancer is amenable to surgical resection. Alternative therapeutic methods for isolated liver metastases include radioembolization with yttrium 90 (Y90) and transarterial chemoembolization (TACE). We present her...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2015/461823 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560409813450752 |
|---|---|
| author | Andre De Souza Kevin Pelham Daly James Yoo Muhammad Wasif Saif |
| author_facet | Andre De Souza Kevin Pelham Daly James Yoo Muhammad Wasif Saif |
| author_sort | Andre De Souza |
| collection | DOAJ |
| description | Background. When associated with isolated four or fewer liver foci, metastatic colorectal cancer is amenable to surgical resection. Alternative therapeutic methods for isolated liver metastases include radioembolization with yttrium 90 (Y90) and transarterial chemoembolization (TACE). We present here a case of a patient with two sites of liver metastatic disease from colorectal cancer who underwent Y90 radioembolization combined with aflibercept and FOLFIRI. Case Report. A 56-year-old female with history of bilateral breast cancer and metastatic colon cancer with prior hemicolectomy and 4 previous chemotherapy regimens developed liver metastasis. She was started on aflibercept and FOLFIRI and concurrently underwent two treatments of radioembolization with Y90, initially targeting the largest right lobe tumor, and then a subsequent treatment targeting the smaller left lobe tumor with retreatment of the right lobe tumor. Her liver metastases exhibited partial response on imaging utilizing the modified RECIST criteria. Interestingly, the patient CEA levels decreased after the procedure. Discussion. This is the first reported case of a patient managed with radioembolization with Y90 combined with aflibercept, an anti-VEGF treatment, and FOLFIRI. An ongoing randomized clinical trial aims to define the role of combined targeted therapy and chemotherapy with radioembolization with Y90. |
| format | Article |
| id | doaj-art-a98d51ba49a9403c9dc4c8834fc0e1b5 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-a98d51ba49a9403c9dc4c8834fc0e1b52025-02-03T01:27:37ZengWileyCase Reports in Oncological Medicine2090-67062090-67142015-01-01201510.1155/2015/461823461823Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal CancerAndre De Souza0Kevin Pelham Daly1James Yoo2Muhammad Wasif Saif3Hematology/Oncology Department, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USAInterventional Radiology Department, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USASurgery Department, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USAHematology/Oncology Department, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USABackground. When associated with isolated four or fewer liver foci, metastatic colorectal cancer is amenable to surgical resection. Alternative therapeutic methods for isolated liver metastases include radioembolization with yttrium 90 (Y90) and transarterial chemoembolization (TACE). We present here a case of a patient with two sites of liver metastatic disease from colorectal cancer who underwent Y90 radioembolization combined with aflibercept and FOLFIRI. Case Report. A 56-year-old female with history of bilateral breast cancer and metastatic colon cancer with prior hemicolectomy and 4 previous chemotherapy regimens developed liver metastasis. She was started on aflibercept and FOLFIRI and concurrently underwent two treatments of radioembolization with Y90, initially targeting the largest right lobe tumor, and then a subsequent treatment targeting the smaller left lobe tumor with retreatment of the right lobe tumor. Her liver metastases exhibited partial response on imaging utilizing the modified RECIST criteria. Interestingly, the patient CEA levels decreased after the procedure. Discussion. This is the first reported case of a patient managed with radioembolization with Y90 combined with aflibercept, an anti-VEGF treatment, and FOLFIRI. An ongoing randomized clinical trial aims to define the role of combined targeted therapy and chemotherapy with radioembolization with Y90.http://dx.doi.org/10.1155/2015/461823 |
| spellingShingle | Andre De Souza Kevin Pelham Daly James Yoo Muhammad Wasif Saif Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer Case Reports in Oncological Medicine |
| title | Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer |
| title_full | Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer |
| title_fullStr | Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer |
| title_full_unstemmed | Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer |
| title_short | Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer |
| title_sort | safety and efficacy of combined yttrium 90 resin radioembolization with aflibercept and folfiri in a patient with metastatic colorectal cancer |
| url | http://dx.doi.org/10.1155/2015/461823 |
| work_keys_str_mv | AT andredesouza safetyandefficacyofcombinedyttrium90resinradioembolizationwithafliberceptandfolfiriinapatientwithmetastaticcolorectalcancer AT kevinpelhamdaly safetyandefficacyofcombinedyttrium90resinradioembolizationwithafliberceptandfolfiriinapatientwithmetastaticcolorectalcancer AT jamesyoo safetyandefficacyofcombinedyttrium90resinradioembolizationwithafliberceptandfolfiriinapatientwithmetastaticcolorectalcancer AT muhammadwasifsaif safetyandefficacyofcombinedyttrium90resinradioembolizationwithafliberceptandfolfiriinapatientwithmetastaticcolorectalcancer |